Kato, Ken

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 373

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer

Nanoparticle-Based Drug DeliveryCancer Treatment and Pharmacology

Cited by 290

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs

Gastric Cancer Management and OutcomesCancer Treatment and Pharmacology

Cited by 237

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 231

Prognostic factors in patients receiving neoadjuvant 5‐fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015) · Oncology

Esophageal Cancer Research and TreatmentGastric Cancer Management and Outcomes

Cited by 36

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., Honma, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 20

Protective and risk factors of impaired awareness of hypoglycemia in patients with type 1 diabetes: A cross-sectional analysis of baseline data from the PR-IAH study

Sakane, N., Kato, K., Hata, S., Nishimura, E., Araki, R., kouyama, K., Hatao, M., Matoba, Y., Matsushita, Y., Domichi, M., et al. (2023) · Diabetology & Metabolic Syndrome

Diabetes Management and ResearchDiabetes Management and Education

Cited by 10

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine

Esophageal Cancer Research and TreatmentCancer Immunotherapy and Biomarkers

Cited by 6

Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., et al. (2024) · Journal of Cancer Research and Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 5

Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2 -Amplified Metastatic Colorectal Cancer

Iida, N., Imai, M., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., et al. (2024) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Cited by 2